Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,248 questions in 108 reviews · Stroke
current versionsNo studies 275 · 22%Ungraded 56 · 4.5%Very low 269 · 21.6%Low 349 · 28%Moderate 216 · 17.3%High 83 · 6.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Active rPMS only vs no intervention Spasticity (elbow) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs no intervention Spasticity (wrist) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs no intervention Muscle strength · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs no intervention Death · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs sham rPMS plus rehabilitation Activities of daily living (ADLs) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | 1 study · 63 participants | Low |
Active rPMS plus rehabilitation vs sham rPMS plus rehabilitation Upper limb function · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | 1 study · 63 participants | Low |
Active rPMS plus rehabilitation vs sham rPMS plus rehabilitation Lower limb function · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs sham rPMS plus rehabilitation Spasticity (elbow) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | 1 study · 63 participants | Low |
Active rPMS plus rehabilitation vs sham rPMS plus rehabilitation Spasticity (wrist) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | 1 study · 63 participants | Low |
Active rPMS only vs sham rPMS Upper limb function · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs sham rPMS plus rehabilitation Muscle strength · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs sham rPMS plus rehabilitation Death · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs rehabilitation only Activities of daily living (ADLs) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs rehabilitation only Upper limb function · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs rehabilitation only Lower limb function · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs rehabilitation only Spasticity (elbow) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs rehabilitation only Spasticity (wrist) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs rehabilitation only Muscle strength · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS plus rehabilitation vs rehabilitation only Death · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs sham rPMS Lower limb function · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs sham rPMS Spasticity (elbow) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs sham rPMS Spasticity (wrist) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs sham rPMS Muscle strength · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | 1 study · 18 participants | Low |
Active rPMS only vs sham rPMS Death · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs no intervention Activities of daily living (ADLs) · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Active rPMS only vs no intervention Upper limb function · people with stroke Repetitive peripheral magnetic stimulation for impairment and disability in people after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Primary outcome: efficacy (functional outcome) · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | RR 0.78 [0.36, 1.68] | 1 study · 40 participants | Very low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Recurrent events (both ischaemic and haemorrhagic stroke) · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | RR 0.69 [0.31, 1.55] | 3 studies · 1819 participants | Low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Incidence of other type of stroke ‒ not measured · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Adverse events · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | RR 0.94 [0.56, 1.58] | 1 study · 1455 participants | Low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Quality of life ‒ not measured · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Mood · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | no estimate extracted | 1 study · 14 participants | Low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Vascular‐related death · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | no estimate extracted | 2 studies · 142 participants | Low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Recurrent events: fatal or non‐fatal (same type of stroke, i.e. ischaemic or haemorrhagic) · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | RR 0.41 [0.02, 8.84] | 1 study · 18 participants | Very low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Incidence of other type of stroke (ischaemic or haemorrhagic): fatal or non‐fatal · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | no estimate extracted | 2 studies · 58 participants | Very low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Adverse events · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | no estimate extracted | 2 studies · 57 participants | Very low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Health‐related quality of life · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | no estimate extracted | 1 study · 102 participants | Low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Mood · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | no estimate extracted | 1 study · 102 participants | Low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Primary outcome: Efficacy (functional outcome) · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | no estimate extracted | 1 study · 52 participants | Very low |
Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy Vascular‐related death · stroke and/or TIA Marine‐derived n‐3 fatty acids therapy for stroke (2022) · Cochrane | RR 1.02 [0.78, 1.35] | 5 studies · 2237 participants | Low |
General anaesthesia vs non‐general anaesthesia Functional outcome (continuous; mRS) · acute ischaemic stroke endovascular treatment Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | 1 study · 90 participants | Very low |
General anaesthesia vs non‐general anaesthesia Neurological impairment (NIHSS) · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | NR | No studies |
General anaesthesia vs non‐general anaesthesia Stroke‐related mortality · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | RR 0.88 [0.64, 1.22] | 6 studies · 843 participants | Low |
General anaesthesia vs non‐general anaesthesia All intracranial haemorrhage · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | NR | No studies |
General anaesthesia vs non‐general anaesthesia Target artery revascularisation status · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | NR | No studies |
General anaesthesia vs non‐general anaesthesia Time to revascularisation · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | NR | No studies |
General anaesthesia vs non‐general anaesthesia Adverse events · acute ischaemic stroke endovascular treatment (long‐term) Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | NR | No studies |
General anaesthesia vs non‐general anaesthesia Neurological impairment (NIHSS) · acute ischaemic stroke endovascular treatment Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | no estimate extracted | 7 studies · 982 participants | Low |
General anaesthesia vs non‐general anaesthesia Stroke‐related mortality · acute ischaemic stroke endovascular treatment Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | RR 0.98 [0.52, 1.84] | 3 studies · 330 participants | Low |
General anaesthesia vs non‐general anaesthesia All intracranial haemorrhage · acute ischaemic stroke endovascular treatment Type of anaesthesia for acute ischaemic stroke endovascular treatment (2022) · Cochrane | RR 0.92 [0.65, 1.29] | 5 studies · 693 participants | Low |